These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1742848)

  • 1. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M; Workman P
    Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI; Workman P
    Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
    Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
    Wong KH; Koch CJ; Wallen CA; Wheeler KT
    Br J Cancer; 1991 Apr; 63(4):484-8. PubMed ID: 2021530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
    Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High uptake of RSU 1069 and its analogues melanotic melanomas.
    Walling JM; Deacon J; Holliday S; Stratford IJ
    Cancer Chemother Pharmacol; 1989; 24(1):28-32. PubMed ID: 2541936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.
    Jenkins TC; Naylor MA; O'Neill P; Threadgill MD; Cole S; Stratford IJ; Adams GE; Fielden EM; Suto MJ; Stier MA
    J Med Chem; 1990 Sep; 33(9):2603-10. PubMed ID: 2391699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
    Siemann DW
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1115-8. PubMed ID: 2703392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP; Gulyas S; Whitmore GF
    Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI; Workman P
    J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
    Workman P; Walton MI
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
    Siemann DW; Maddison K; Wolf K
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145.
    Siemann DW
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):301-6. PubMed ID: 8195023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
    Sebolt-Leopold JS; Vincent PW; Beningo KA; Elliott WL; Leopold WR; Heffner TG; Wiley JN; Stier MA; Suto MJ
    Int J Radiat Oncol Biol Phys; 1992; 22(3):549-51. PubMed ID: 1531213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.
    Cobb LM; Nolan J; Butler SA
    Br J Cancer; 1990 Dec; 62(6):915-8. PubMed ID: 2257219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin.
    Roizin-Towle L; Pirro JP; Hall EJ
    Radiat Res; 1990 Oct; 124(1 Suppl):S50-5. PubMed ID: 2236511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of RSU-1069 for KHT cells treated in vivo or in vitro: evidence for a diffusible toxic product.
    Hill RP; Gulyas S; Whitmore GF
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1111-4. PubMed ID: 2703391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitization of lomustine by misonidazole, benznidazole, and RSU 1069.
    Workman P
    Cancer Treat Rep; 1986 Sep; 70(9):1139-40. PubMed ID: 3755651
    [No Abstract]   [Full Text] [Related]  

  • 20. Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
    Siemann DW; Sutherland RM
    Radiother Oncol; 1992 Aug; 24(4):239-45. PubMed ID: 1410579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.